Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

NEOSTIGMINE IMPURITY A CRS (0.003 MG)

NEOSTIGMINE IMPURITY A CRS (0.003 MG)

NA

DISCOVER
INDOMETACIN IMPURITY MIXTURE CRS (0.002 MG)

INDOMETACIN IMPURITY MIXTURE CRS (0.002 MG)

53-86-1

DISCOVER
Zidovudine for system suitability CRS, 10mg

Zidovudine for system suitability CRS, 10mg

30516-87-1

DISCOVER
CAPECITABINE CRS (150 MG)

CAPECITABINE CRS (150 MG)

154361-50-9

DISCOVER
CAPECITABINE IMPURITY A CRS (5 MG)

CAPECITABINE IMPURITY A CRS (5 MG)

66335-38-4

DISCOVER
CAPECITABINE IMPURITY B CRS (15 MG)

CAPECITABINE IMPURITY B CRS (15 MG)

154361-50-9

DISCOVER
CAPECITABINE IMPURITY D CRS (15 MG)

CAPECITABINE IMPURITY D CRS (15 MG)

154361-50-9

DISCOVER
VARDENAFIL HYDROCHLORIDE CRS (130 MG)

VARDENAFIL HYDROCHLORIDE CRS (130 MG)

330808-88-3

DISCOVER
VARDENAFIL FOR SYSTEM SUITABILITY CRS (10 MG)

VARDENAFIL FOR SYSTEM SUITABILITY CRS (10 MG)

NA

DISCOVER
ARIPIPRAZOLE CRS (170 MG)

ARIPIPRAZOLE CRS (170 MG)

129722-12-9

DISCOVER
ARIPIPRAZOLE IMPURITY F CRS (15 MG)

ARIPIPRAZOLE IMPURITY F CRS (15 MG)

573691-09-5

DISCOVER
CILASTATIN FOR SYSTEM SUITABILITY 1 CRS (5 MG)

CILASTATIN FOR SYSTEM SUITABILITY 1 CRS (5 MG)

81129-83-1

DISCOVER